Atherosclerosis, 69 (1988) 281–283
Elsevier Scientific Publishers Ireland, Ltd.

Author Index (Vol. 69)

Adams, C.W.M., see Keohane, S.G., 103
Albers, J.J., see Miller, N.E., 123
Amy, R.M., Dolphin, P.J., Pederson, R.A. and Russell, J.C., Atherogenesis in two strains of obese rats. The fatty Zucker and LA/N-corpulent, 199
Aoyama, H., Mori, N. and Mori, W., Effects of melatonin on genetic hypercholesterolemia in rats, 269
Aursnes, I., Smith, P., Christiansen, E.N., and Berg, K., Factor analysis of plasma lipoprotein components, 219
Avogaro, P., Cazzolato, G. and Bittolo Bon, G., A question concerning apo B-48 (Letter to the Editor), 273

Ball, M., see Jenner, K., 39
Baralle, F.E., see Jenner, K., 39
Baskerville, P., see Shaikh, M., 165
Berg, K., see Aursnes, I., 219
Berguer, R., see Kessel, D., 1
Bittolo Bon, G., see Avogaro, P., 273
Bowyer, D.E., see Jackson, C.L., 115
Brown, W.E., see Tomazic, B.B., 5
Browse, N.L., see Shaikh, M., 165
Bujo, H., see Saito, Y., 161
Bush, R.C., see Jackson, C.L., 115

Caslake, M.J., see Series, J.J., 233
Cazzolato, G., see Avogaro, P., 273
Christiansen, E.N., see Aursnes, I., 219
Cremer, P., see Siegrist, J., 211
Cruickshank, A., see Series, J.J., 233
Czekelius, P., see Steinmetz, A., 21

Delcroix, C., see Malmendier, C.L., 51
Demacker, P.N.M., Hijmans, A.G.M., Stalenhoef, A.F.H. and Van't Laar, A., Studies on the function of hepatic lipase in the cat after immunological blockade of the enzyme in vivo, 173
Demant, T., see Series, J.J., 233
Diehl, A.K., Fuller, J.H., Mattock, M.B., Salter, A.M., El-Gohari, R. and Keen, H., The relationship of high density lipoprotein subfractions to alcohol consumption, other lifestyle factors, and coronary heart disease, 145
Dolphin, P.J., see Amy, R.M., 199
Duffield, R., see Shaikh, M., 165

El-Gohari, R., see Diehl, A.K., 145
Erkelens, D.W., see Mol, M.J.T.M., 131

Faris, B., see Ohishi, H., 61
Fears, R., Ferres, H., Haacke, H., Mäder, C. and Parwaresch, M.R., Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and Complamin®, 97
Ferres, H., see Fears, R., 97
Franzblau, C., see Ohishi, H., 61
Franzblau, C., see Schreiber, B.M., 69
Friedlander, Y., see Simons, L.A., 139
Fuller, J.H., see Diehl, A.K., 145

Gevers Leuven, J.A., see Mol, M.J.T.M., 131
Giudici, G., see Jenner, K., 39
Grab, B., see Hong, M.L., 241
Grutman, G.A., see Malmendier, C.L., 51

Haacke, H., see Fears, R., 97
Hausmann, J., see Ohishi, H., 61
Hess, D., see Ohishi, H., 61
Hijmans, A.G.M., see Demacker, P.N.M., 173
Hollander, W., see Schreiber, B.M., 69
Hong, M.L., James, R.W., Grab, B. and Pometta, D., High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hyperglyceridaemia on subfraction concentration and composition, 241
Hüther, A.M., see Rücker, W., 155

Jaakkola, O., Kallioniemi, O.-P. and Nikkari, T., Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study, 257
Jackson, C.L., Bush, R.C. and Bowyer, D.E., Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size, 115
James, R.W., see Hong, M.L., 241
Jenner, K., Sidoli, A., Ball, M., Rodriguez, J.R., Pagani, F., Giudici, G., Vergani, C., Mann, J., Baralle, F.E. and Shoulders, C.C., Characterization of genetic markers in the 3′ end of the apo B gene and their use in family and population studies, 39

Kaffarnik, H., see Steinmetz, A., 21
Kallioniemi, O.-P., see Jaakkola, O., 257
Kark, J.D., see Simons, L.A., 139
Keen, H., see Diehl, A.K., 145

0021-9150/88/$03.50 © 1988 Elsevier Scientific Publishers Ireland, Ltd.

Keohane, S.G., Adams, C.W.M. and Poston, R.N., Coronary arterial dimensions and cell populations in ageing man, 103
Kessel, D. and Berguer, R., Determinants of porphyrin fluorescence emission spectra of atheromatous plaques, 1
Kilday, C., see Series, J.J., 233
Klurfeld, D.M., see Kritchevsky, D., 89
Kobori, S., Nakamura, N., Uzawa, H. and Shichiri, M., Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan, 81
Kosakai, M., see Ohishi, H., 61
Kritchevsky, D., Tepper, S.A. and Klurfeld, D.M., Flordipine, a calcium channel blocker, which does not influence lipidemia or atherosclerosis in cholesterol-fed rabbits (Preliminary Note), 89
Kuusi, T., see Sorva, R., 191

La Ville, A.E., see Shaikh, M., 165
Lewis, B., see Shaikh, M., 165
Lontie, J.-F., see Malmendier, C.L., 51

Madec, Y., see Mainard, F., 225
Mäder, C., see Fears, R., 97
Mainard, F., Ozanne, P. and Madec, Y., Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction, 225
Malmendier, C.L., Lontie, J.-F., Grutman, G.A. and Delcroix, C., Metabolism of apolipoprotein C-III in normolipemic human subjects, 51
Mann, J., see Jenner, K., 39
Martin, B.M., see Schreiber, B.M., 69
Martini, S., see Shaikh, M., 165
Matschinger, H., see Siegrist, J., 211
Mattock, M.B., see Diehl, A.K., 145
Miller, N.E., Rajput-Williams, J., Nanjee, M.N. Samuel, L. and Albers, J.J., Relationship of high density lipoprotein composition to plasma lecithin : cholesterol acyltransferase concentration in men, 123
Mogayzel, Jr., P.J., see Ohishi, H., 61
Mol, M.J.T.M., Erkelens, D.W., Gevers Leuven, J.A., Schouten, J.A. and Stalenhoef, A.F.H., Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia, 131
Mori, N., see Aoyama, H., 269
Mori, W., see Aoyama, H., 269
Morisaki, N., see Saito, Y., 161
Motzny, S., see Steinmetz, A., 21

Nakamura, N., see Kobori, S., 81
Nanjee, M.N., see Miller, N.E., 123
Nikkari, T., see Jaakkola, O., 257
Nikkilä, E.A., see Sorva, R., 191
Nikkilä, E.A., see Taskinen, M.-R., 249

Ohishi, H., Hess, D., Kosakai, M., Schmid, K., Hausmann, J., Mogayzel, Jr., P.J., Faris, B. and Franzblau, C., Glycosaminoglycan content in neonatal rat aortic smooth muscle cell cultures, 61
Olpin, S.E. and Price, C.P., High density lipoprotein and apolipoprotein A-I in acute phase response (letter to the Editor), 93
Olszewski, A.J. and Szostak, W.B., Homocysteine content of plasma proteins in ischemic heart disease, 109
Ozanne, P., see Mainard, F., 225

Packard, C.J., see Series, J.J., 233
Pagani, F., see Jenner, K., 39
Parwaresch, M.R., see Fears, R., 97
Patsch, W., see Tamai, T., 29
Pederson, R.A., see Amy, R.M., 199
Perheentupa, J., see Sorva, R., 191
Poapst, M., Uffelman, K. and Steiner, G., A question concerning apo B-48: A reply to the letter by P. Avogaro, G.G. Gazzolato and G. Bittolo Bon (Letter to the Editor), 275
Pometta, D., see Hong, M.L., 241
Poston, R.N., see Keohane, S.G., 103
Price, C.P., see Olpin, S.E., 93
Prop, G., see Rücker, W., 155

Queral, L.A., see Tomazic, B.B., 5
Quiney, J.R., see Shaikh, M., 165

Rajput-Williams, J., see Miller, N.E., 123
Rodriguez, J.R., see Jenner, K., 39
Russell, J.C., see Amy, R.M., 199
Rücker, W., Prop, G. and Hüther, A.M., Antiatherosclerotic and antihyperlipidemic effects of octimibate sodium in rabbits, 155

Sachinidis, A., see Zidek, W., 185
Sadovnik, M., see Tomazic, B.B., 5
Saito, Y, Bujo, H., Morisaki, N., Shirai, K. and Yoshida, S., Proliferation and LDL binding of cultured intimal smooth muscle cells from rabbits, 161
Salter, A.M., see Diehl, A.K., 145
Samuel, L., see Miller, N.E., 123
Schmid, K., see Ohishi, H., 61
Schonfeld, G., see Tamai, T., 29
Schouten, J.A., see Mol, M.J.T.M., 131
Schreiber, B.M., Martin, B.M., Hollander, W. and Franzblau, C., β-VLDL-induced alterations in growth potentiating activity produced by mononuclear phagocytes, 69
Seidel, D., see Siegrist, J., 211
Series, J.J., Caslake, M.J., Kilday, C., Cruickshank, A., Demant, T., Packard, C.J. and Shepherd, J., Influence of etofibrate on low density lipoprotein metabolism, 233
Shaikh, M., Martini, S., Quiney, J.E., Baskerville, P., La Ville, A.E., Browse, N.L., Duffield, R., Turner, P.R. and Lewis, B., Modified plasma-derived lipoproteins in human atherosclerotic plaques, 165
Shepherd, J., see Series, J.J., 233
Shichiri, M., see Kobori, S., 81
Shirai, K., see Saito, Y., 161
Shoulders, C.C., see Jenner, K., 39
Sidoli, A., see Jenner, K., 39
Siegrist, J., Matschinger, H., Cremer, P. and Seidel, D., Atherogenic risk in men suffering from occupational stress, 211

Simons, J., see Simons, L.A., 139
Simons, L.A., Friedlander, Y., Simons, J. and Kark, J.D., Familial aggregation of coronary heart disease: partial mediation by high density lipoproteins?, 139
Smith, P., see Aursnes, I., 219
Sorva, R., Kuusi, T., Taskinen, M.-R., Perheentupa, J. and Nikkilä, E.A., Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males, 191
Spieker, C., see Zidek, W., 185
Stalenhoef, A.F.H., see Demacker, P.N.M., 173
Stalenhoef, A.F.H., see Mol, M.J.T.M., 131
Steiner, G., see Poapst, M., 275
Steinmetz, A., Czekelius, P., Thiemann, E., Motzny, S. and Kaffarnik, H., Changes of apolipoprotein A-IV in the human neonate: evidence for different inductions of apolipoproteins A-IV and A-I in the postpartum period, 21
Storkebaum, W., see Zidek, W., 185
Szostak, W.B., see Olszewski, A.J., 109

Tamai, T., Patsch, W. and Schonfeld, G., Regulation of lipoprotein receptors on a rat hepatoma cell line, 29
Taskinen, M.-R. and Nikkilä, E.A., Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia, 249
Taskinen, M.-R., see Sorva, R., 191
Tepper, S.A., see Kritchevsky, D., 89
Thiemann, E., see Steinmetz, A., 21
Tomazic, B.B., Brown, W.E., Queral, L.A. and Sadovnik, M., Physicochemical characterization of cardiovascular calcified deposits. I. Isolation, purification and instrumental analysis, 5
Turner, P.R., see Shaikh, M., 165

Uffelman, K., see Poapst, M., 275
Uzawa, H., see Kobori, S., 81

Van 't Laar, A., see Demacker, P.N.M., 173
Vergani, C., see Jenner, K., 39

Yoshida, S., see Saito, Y., 161

Zidek, W., Sachinidis, A., Spieker, C. and Storkebaum, W., Effect of hypertensive plasma on Ca^{2+} transport in human neutrophils, 185

Atherosclerosis, 69 (1988) 284–287
Elsevier Scientific Publishers Ireland, Ltd.

Subject Index (Vol. 69)

ACAT inhibitor
–, Atherosclerosis; Rabbits; Cholesterol-rich diet; Octimibate sodium, 155
Acetylated LDL
–, Atherosclerosis; Cell proliferation; Foam cell; Intimal smooth muscle cells; LDL, 161
–, Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Macrophages; Smooth muscle cells, 257
Acipimox
–, Lipoproteins; HDL; Lipolytic enzymes; Hypertriglyceridemia, 249
Ageing
–, Arteritis; Atherosclerosis; Coronary artery; Image analysis; Lymphocyte, 103
Alcohol
–, Lipoproteins; HDL subfractions; Obesity; Coronary heart disease, 145
α-Aminoadipic acid
–, Atherosclerosis; Homocysteine; Human plasma; Homocysteine-cysteine mixed disulfide, 109
Animal model
–, Hepatic triglyceride lipase; Chylomicrons; Lipoproteins; Postprandial phase; Apoproteins, 173
Antihypercholesterolemic effect
–, Melatonin; Genetically hypercholesterolemic rat, 269
Antihypertensive agents
–, Calcium antagonists; Balloon catheter; Smooth muscle cell proliferation; Nifedipine, 115
Aortic smooth muscle cell cultures (rat)
–, Glycosaminoglycans; Ascorbate, 61
Apo A-I
–, HDL subfractions; Hypertriglyceridemia; Cardiovascular patients; Apo A-II, 241
Apo A-II
–, HDL subfractions; Hypertriglyceridemia; Cardiovascular patients; Apo A-I, 241
Apo B genetic markers
–, Hyperlipidemia; Hypervariable region, 39
Apolipoprotein(s)
–, Apolipoprotein E polymorphism; Lipids; Hyperlipoproteinemia type III, 81
–, Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219
–, Familial hypercholesterolemia; Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Lipoproteins, 131
Apolipoproteins, *see also under* Apo
Apolipoprotein C-III turnover
–, Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton–Hunter labeling; Iodine monochloride labeling, 51
Apolipoprotein E polymorphism
–, Lipids; Apolipoproteins; Hyperlipoproteinemia type III, 81
Apolipoprotein polymorphism
–, Immunoblotting; Umbilical cord apoproteins; Fat absorption, 21
Apoprotein(s)
–, Arterial lipoproteins; Macrophages; Scavenger receptor, 165
–, Hepatic triglyceride lipase; Animal model; Chylomicrons; Lipoproteins; Postprandial phase, 173
–, Myocardial infarction; Lipids; Lipoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
–, Testosterone; HDL-cholesterol; Hepatic lipase; Lipoprotein lipase, 191
Arterial lipoprotein(s)
–, Apoproteins; Macrophages; Scavenger receptor, 165
Arteritis
–, Ageing; Atherosclerosis; Coronary artery; Image analysis; Lymphocyte, 103
Ascorbate
–, Aortic smooth muscle cell cultures (rat); Glycosaminoglycans, 61
Atherogenic risk
–, Ratio between LDL and HDL; Job insecurity; Shift work, 211
Atheromatous plaques
–, LDL; Porphyrins, 1
Atherosclerosis
–, Acetylated LDL; Fluorescently labelled lipoproteins; LDL; Macrophages; Smooth muscle cells, 257
–, Ageing; Arteritis; Coronary artery; Image analysis; Lymphocyte, 103
–, α-Aminoadipic acid; Homocysteine; Human plasma; Homocysteine-cysteine mixed disulfide, 109
–, Apolipoproteins; Cholesterol; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219
–, Calcium channel blockers; Cholesterol; Flordipine; Liver lipids; Serum lipids, 89
–, Cell proliferation; Foam cell; Intimal smooth muscle cells; LDL; Acetylated LDL, 161
–, Growth potentiating activity; Mononuclear phagocytes; Foam cells; β-VLDL, 69
–, Hyperlipidemia; Hyperinsulinemia; Myocardial lesions; Scanning electron microscopy, 199

0021-9150/88/$03.50 © 1988 Elsevier Scientific Publishers Ireland, Ltd.

–, Rabbits; Cholesterol-rich diet; ACAT inhibitor; Octimibate sodium, 155

Balloon catheter
–, Calcium antagonists; Smooth muscle cell proliferation; Nifedipine; Antihypertensive agents, 115
Blood glucose
–, Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Insulin; Cortisol; Vanillylmandelic acid, 225
Bolton–Hunter labeling
–, Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Iodine monochloride labeling, 51

Calcium antagonists
–, Balloon catheter; Smooth muscle cell proliferation; Nifedipine; Antihypertensive agents, 115
–Calcium channel blockers
–, Atherosclerosis; Cholesterol; Flordipine; Liver lipids; Serum lipids, 89
Calcium ion
–, Essential hypertension; Neutrophils, 185
Carbonate apatite
–, Cardiovascular mineral; Hydroxyapatite; Octacalcium phosphate; Physicochemical characterization, 5
Cardiovascular mineral
–, Hydroxyapatite; Octacalcium phosphate; Carbonate apatite; Physicochemical characterization, 5
Cardiovascular patients
–, HDL subfractions; Hypertriglyceridemia; Apo A-I; Apo A-II, 241
Cell density
–, Lipoprotein receptor; Regulation; Lipoprotein deficient serum, 29
Cell proliferation
–, Atherosclerosis; Foam cell; Intimal smooth muscle cells; LDL; Acetylated LDL, 161
Cholesterol
–, Apolipoproteins; Atherosclerosis; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219
–, Atherosclerosis; Calcium channel blockers; Flordipine; Liver lipids; Serum lipids, 89
–, Familial hypercholesterolemia; Hydroxymethylglutaryl-coenzyme A reductase; Lipoprotein; Apolipoprotein, 131
Cholesterol-rich diet
–, Atherosclerosis; Rabbits; ACAT inhibitor; Octimibate sodium, 155
Cholestyramine
–, Complamin®; Combination therapy; Hyperlipoproteinemia; LDL; HDL, 97
Chylomicrons
–, Hepatic triglyceride lipase; Animal model; Lipoproteins; Postprandial phase; Apoproteins, 173
Combination therapy
–, Complamin®; Cholestyramine; Hyperlipoproteinemia; LDL; HDL, 97
Complamin®
–, Cholestyramine; Combination therapy; Hyperlipoproteinemia; LDL; HDL, 97

Coronary artery
–, Ageing, Arteritis; Atherosclerosis; Image analysis; Lymphocyte, 103
Coronary heart disease
–, Family history; HDL-cholesterol; Cross-sectional study, 139
–, Lipoproteins, HDL subfractions; Alcohol; Obesity, 145
Cortisol
–, Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Vanillylmandelic acid, 225
Cross-sectional study
–, Coronary heart disease; Family history; HDL-cholesterol, 139

Essential hypertension
–, Calcium ion; Neutrophils, 185

Factor analysis
–, Apolipoproteins; Atherosclerosis; Cholesterol; Fatty acids; Lipoproteins; Triglycerides, 219
Familial hypercholesterolemia
–, Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Lipoprotein; Apolipoprotein, 131
Family history
–, Coronary heart disease; HDL-cholesterol; Cross-sectional study, 139
Fat absorption
–, Apolipoprotein polymorphism; Immunoblotting; Umbilical cord apoproteins, 21
Fatty acids
–, Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Lipoproteins; Triglycerides, 219
Flordipine
–, Atherosclerosis; Calcium channel blockers; Cholesterol; Liver lipids; Serum lipids 89
Fluorescently labelled lipoproteins
–, Acetylated LDL; Atherosclerosis; LDL; Macrophages; Smooth muscle cells, 257
Foam cell(s)
–, Atherosclerosis; Cell proliferation; Intimal smooth muscle cells; LDL; Acetylated LDL, 161
–, Growth potentiating activity; Mononuclear phagocytes; β-VLDL; Atherosclerosis, 69
Fractional clearance rate
–, LDL catabolism (receptor-mediated and receptor-independent); Synthetic rate; HDL, 233

Genetically hypercholesterolemic rat
–, Melatonin; Antihypercholesterolemic effect, 269
Glycosaminoglycans
–, Aortic smooth muscle cell cultures (rat); Ascorbate, 61
Growth potentiating activity
–, Mononuclear phagocytes; Foam cells; β-VLDL; Atherosclerosis, 69

HDL
–, Complamin®; Cholestyramine; Combination therapy; Hyperlipoproteinemia; LDL, 97
–, LDL catabolism (receptor-mediated and receptor-independent); Fractional clearance rate; Synthetic rate, 233

–, Plasma lecithin:cholesterol acyltransferase; Plasma concentration; HDL-cholesterol, 123
HDL-cholesterol
–, Coronary heart disease; Family history; Cross-sectional study, 139
–, HDL; Plasma lecithin:cholesterol acyltransferase; Plasma concentration, 123
–, Testosterone; Apoproteins; Hepatic lipase; Lipoprotein lipase, 191
HDL subfractions
–, Hypertriglyceridemia; Cardiovascular patients; Apo A-I; Apo A-II, 241
–, Lipoproteins; Alcohol; Obesity; Coronary heart disease, 145
Hepatic lipase
–, Testosterone; HDL-cholesterol; Apoproteins; Lipoprotein lipase, 191
Hepatic triglyceride lipase
–, Animal model; Chylomicrons; Lipoproteins; Postprandial phase; Apoproteins, 173
High density lipoproteins, *see also under* HDL
Homocysteine
–, α-Aminoadipic acid; Atherosclerosis; Human plasma; Homocysteine-cysteine mixed disulfide, 109
Homocysteine-cysteine mixed disulfide
–, α-Aminoadipic acid; Atherosclerosis; Homocysteine; Human plasma, 109
Human plasma
–, α-Aminoadipic acid; Atherosclerosis; Homocysteine; Homocysteine-cysteine mixed disulfide, 109
Hydroxyapatite
–, Cardiovascular mineral; Octacalcium phosphate; Carbonate apatite; Physicochemical characterization, 5
Hydroxymethylglutaryl-coenzyme A reductase
–, Familial hypercholesterolemia; Cholesterol; Lipoprotein; Apolipoprotein, 131
Hyperinsulinemia
–, Atherosclerosis; Hyperlipidemia; Myocardial lesions; Scanning electron microscopy, 199
Hyperlipidemia
–, Apo B genetic markers; Hypervariable region, 39
–, Atherosclerosis; Hyperinsulinemia; Myocardial lesions; Scanning electron microscopy, 199
Hyperlipoproteinemia
–, Complamin®; Cholestyramine; Combination therapy; LDL; HDL, 97
Hyperlipoproteinemia type III
–, Apolipoprotein E polymorphism; Lipids; Apolipoproteins, 81
Hypertriglyceridemia
–, HDL subfractions; Cardiovascular patients; Apo A-I; Apo A-II, 241
–, Lipoproteins; HDL; Acipimox; Lipolytic enzymes, 249
Hypervariable region
–, Hyperlipidemia; Apo B genetic markers, 39

Image analysis
–, Ageing; Arteritis; Atherosclerosis; Coronary artery; Lymphocyte, 103
Immunoblotting
–, Apolipoprotein polymorphism; Umbilical cord apoproteins; Fat absorption, 21
Insulin
–, Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Cortisol; Vanillylmandelic acid, 225
Intimal smooth muscle cells
–, Atherosclerosis; Cell proliferation; Foam cell; LDL; Acetylated LDL, 161
In vivo kinetics
–, Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; Plasma; Urine; Bolton–Hunter labeling; Iodine monochloride labeling, 51
Iodine monochloride labeling
–, Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton–Hunter labeling, 51

Job insecurity
–, Atherogenic risk; Ratio between LDL and HDL; Shift work, 211

LDL
–, Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; Macrophages; Smooth muscle cells, 257
–, Atheromatous plaques; Porphyrins, 1
–, Atherosclerosis; Cell proliferation; Foam cell; Intimal smooth muscle cells Acetylated LDL, 161
–, Complamin®; Cholestyramine; Combination therapy; Hyperlipoproteinemia; HDL, 97
LDL catabolism (receptor-mediated and receptor-independent)
–, Fractional clearance rate; Synthetic rate; HDL, 233
Lipids
–, Apolipoprotein E polymorphism; Apolipoproteins; Hyperlipoproteinemia type III, 81
–, Myocardial infarction; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
Lipolytic enzymes
–, Lipoproteins; HDL; Acipimox; Hypertriglyceridemia, 249
Lipoprotein(s)
–, Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Triglycerides, 219
–, Familial hypercholesterolemia; Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Apolipoprotein, 131
–, HDL; Acipimox; Lipolytic enzymes; Hypertriglyceridemia, 249
–, HDL subfractions; Alcohol; Obesity; Coronary heart disease, 145
–, Hepatic triglyceride lipase; Animal model; Chylomicrons; Postprandial phase; Apoproteins, 173
–, Myocardial infarction; Lipids; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
Lipoprotein deficient serum
–, Lipoprotein receptor; Regulation; Cell density, 29
Lipoprotein fractions
–, Apolipoprotein C-III turnover; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton–Hunter labeling; Iodine monochloride labeling, 51

Lipoprotein lipase
–, Testosterone; HDL-cholesterol; Apoproteins; Hepatic lipase, 191
Lipoprotein receptor
–, Regulation; Cell density; Lipoprotein deficient serum, 29
Liver lipids
–, Atherosclerosis; Calcium channel blockers; Cholesterol; Flordipine; Serum lipids, 89
Low density lipoproteins, *see also under* LDL
Lymphocyte
–, Ageing; Arteritis; Atherosclerosis; Coronary artery; Image analysis, 103

Macrophages
–, Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Smooth muscle cells, 257
–, Arterial lipoproteins; Apoproteins; Scavenger receptor, 165
Melatonin
–, Genetically hypercholesterolemic rat; Antihypercholesterolemic effect, 269
Metabolism
–, Apolipoprotein C-III turnover; Lipoprotein fractions; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton–Hunter labeling; Iodine monochloride labeling, 51
Mononuclear phagocytes
–, Growth potentiating activity; Foam cells; β-VLDL; Atherosclerosis, 69
Myocardial infarction
–, Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
Myocardial lesions
–, Atherosclerosis; Hyperlipedemia; Hyperinsulinemia; Scanning electron microscopy, 199

Neutrophils
–, Calcium ion; Essential hypertension, 185
Nifedipine
–, Calcium antagonists; Balloon catheter; Smooth muscle cell proliferation; Antihypertensive agents, 115
Normal subjects
–, Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; In vivo kinetics; Plasma; Urine; Bolton–Hunter labeling; Iodine monochloride labeling, 51

Obesity
–, Lipoproteins; HDL subfractions; Alcohol; Coronary heart disease, 145
Octacalcium phosphate
–, Cardiovascular mineral; Hydroxyapatite; Carbonate apatite; Physicochemical characterization, 5
Octimibate sodium
–, Atherosclerosis; Rabbits; Cholesterol-rich diet; ACAT inhibitor, 155

Physicochemical characterization
–, Cardiovascular mineral; Hydroxyapatite; Octacalcium phosphate; Carbonate apatite, 5
Plasma
–, Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Urine; Bolton–Hunter labeling; Iodine monochloride labeling, 51
Plasma concentration
–, HDL; Plasma lecithin:cholesterol acyltransferase; HDL-cholesterol, 123
Plasma lecithin:cholesterol acyltransferase
–, HDL; Plasma concentration; HDL-cholesterol, 123
Porphyrins
–, Atheromatous plaques, LDL, 1
Postprandial phase
–, Hepatic triglyceride lipase; Animal model; Chylomicrons; Lipoproteins; Apoproteins, 173

Rabbits
–, Atherosclerosis; Cholesterol-rich diet; ACAT inhibitor; Octimibate sodium, 155
Ratio between LDL and HDL
–, Atherogenic risk; Job insecurity; Shift work, 211
Regulation
–, Lipoprotein receptor; Cell density; Lipoprotein deficient serum, 29

Scanning electron microscopy
–, Atherosclerosis; Hyperlipidemia; Hyperinsulinemia; Myocardial lesions, 199
Scavenger receptor
–, Arterial lipoproteins; Apoproteins; Macrophages, 165
Serum lipids
–, Atherosclerosis; Calcium channel blockers; Cholesterol; Flordipine; Liver lipids, 89
Shift work
–, Atherogenic risk; Ratio between LDL and HDL; Job insecurity, 211
Smooth muscle cell(s)
–, Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Macrophages, 257
Smooth muscle cell proliferation
–, Calcium antagonists; Balloon catheter; Nifedipine; Antihypertensive agents, 115
Synthetic rate
–, LDL catabolism (receptor-mediated and receptor-independent); Fractional clearance rate; HDL, 233

Testosterone
–, HDL-cholesterol; Apoproteins; Hepatic lipase; Lipoprotein lipase, 191
Triglycerides
–, Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Lipoproteins, 219

Umbilical cord apoproteins
–, Apolipoprotein polymorphism; Immunoblotting; Fat absorption, 21
Urine
–, Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Bolton–Hunter labeling; Iodine monochloride labeling, 51

Vanillylmandelic acid
–, Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol, 225
Very low density lipoproteins, *see also under* VLDL
β-VLDL
–, Growth potentiating activity; Mononuclear phagocytes; Foam cells; Atherosclerosis, 69

(Contents continued from back cover)

Atherogenic risk in men suffering from occupational stress (ATH 04071)
J. Siegrist, H. Matschinger, P. Cremer and D. Seidel (F.R.G.) 211
Factor analysis of plasma lipoprotein components (ATH 04076)
I. Aursnes, P. Smith, E.N. Christiansen and K. Berg (Norway) 219
Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction (ATH 04077)
F. Mainard, P. Ozanne and Y. Madec (France) 225
Influence of etofibrate on low density lipoprotein metabolism (ATH 04078)
J.J. Series, M.J. Caslake, C. Kilday, A. Cruickshank, T. Demant, C.J. Packard and J. Shepherd (U.K.) 233
High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hypertriglyceridaemia on subfraction concentration and composition (ATH 04079)
M.L. Hong, R.W. James, B. Grab and D. Pometta (Switzerland) 241
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia (ATH 04080)
M.-R. Taskinen and E.A. Nikkilä (Finland) 249
Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study (ATH 04081)
O. Jaakkola, O.-P. Kallioniemi and T. Nikkari (Finland) 257
Effects of melatonin on genetic hypercholesterolemia in rats (ATH 04066)
H. Aoyama, N. Mori and W. Mori (Japan) 269

Letters to the Editor
A question concerning apo B-48 (ATH 04072)
P. Avogaro, G. Cazzolato and G. Bittolò Bon 273
A question concerning apo B-48. A reply to the letter by P. Avogaro, G. Cazzolato and B. Bittolò Bon (ATH 04073)
M. Poapst and K.U.G. Steiner 275

Erratum 277

Announcements 279

Author Index (Vol. 69) 281

Subject Index (Vol. 69) 284